title: The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain.
abstract: BACKGROUND
  Clinical studies of osteoarthritis (OA) suggest central sensitization may contribute to the chronic pain experienced. This preclinical study used the monosodium iodoacetate (MIA) model of OA joint pain to investigate the potential contribution of spinal sensitization, in particular spinal glial cell activation, to pain behaviour in this model. Experimental OA was induced in the rat by the intra-articular injection of MIA and pain behaviour (change in weight bearing and distal allodynia) was assessed. Spinal cord microglia (Iba1 staining) and astrocyte (GFAP immunofluorescence) activation were measured at 7, 14 and 28 days post MIA-treatment. The effects of two known inhibitors of glial activation, nimesulide and minocycline, on pain behaviour and activation of microglia and astrocytes were assessed.
  
  
  RESULTS
  Seven days following intra-articular injection of MIA, microglia in the ipsilateral spinal cord were activated (p < 0.05, compared to contralateral levels and compared to saline controls). Levels of activated microglia were significantly elevated at day 14 and 21 post MIA-injection. At day 28, microglia activation was significantly correlated with distal allodynia (p < 0.05). Ipsilateral spinal GFAP immunofluorescence was significantly (p < 0.01) increased at day 28, but not at earlier timepoints, in the MIA model, compared to saline controls. Repeated oral dosing (days 14-20) with nimesulide attenuated pain behaviour and the activation of microglia in the ipsilateral spinal cord at day 21. This dosing regimen also significantly attenuated distal allodynia (p < 0.001) and numbers of activated microglia (p < 0.05) and GFAP immunofluorescence (p < 0.001) one week later in MIA-treated rats, compared to vehicle-treated rats. Repeated administration of minocycline also significantly attenuated pain behaviour and reduced the number of activated microglia and decreased GFAP immunofluorescence in ipsilateral spinal cord of MIA treated rats.
  
  
  CONCLUSIONS
  Here we provide evidence for a contribution of spinal glial cells to pain behaviour, in particular distal allodynia, in this model of osteoarthritic pain. Our data suggest there is a potential role of glial cells in the central sensitization associated with OA, which may provide a novel analgesic target for the treatment of OA pain.
authors.affiliation: Arthritis Research UK, Pain Centre, University of Nottingham, Nottingham, UK.
authors.forename: Devi Rani
authors.initials: DR
authors.lastname: Sagar
authors.forename: James J
authors.initials: JJ
authors.lastname: Burston
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Hathway
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Woodhams
authors.forename: Richard G
authors.initials: RG
authors.lastname: Pearson
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Bennett
authors.forename: David A
authors.initials: DA
authors.lastname: Kendall
authors.forename: Brigitte E
authors.initials: BE
authors.lastname: Scammell
authors.forename: Victoria
authors.initials: V
authors.lastname: Chapman
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000473:pathology / Q000502:physiology; D059350:Chronic Pain / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D005455:Fluorescent Antibody Technique; D006930:Hyperalgesia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D007461:Iodoacetates / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008911:Minocycline / Q000494:pharmacology / Q000627:therapeutic use; D009457:Neuroglia / Q000473:pathology / Q000502:physiology*; D055013:Osteoarthritis, Spine / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D010147:Pain Measurement; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology
chemical_list: D007461:Iodoacetates; D008911:Minocycline
references.citation: Toxicol Pathol. 2003 Nov-Dec;31(6):619-24
references.pmid: 14585729
references.citation: J Neurophysiol. 1996 Nov;76(5):3025-37
references.pmid: 8930252
references.citation: Osteoarthritis Cartilage. 2003 Nov;11(11):821-30
references.pmid: 14609535
references.citation: Brain Res. 1989 Jun 5;489(1):113-9
references.pmid: 2501001
references.citation: Biochim Biophys Acta. 2005 Sep 30;1745(3):393-400
references.pmid: 16054711
references.citation: Osteoarthritis Cartilage. 2001 Nov;9(8):751-60
references.pmid: 11795995
references.citation: Pain. 2010 Feb;148(2):309-319
references.pmid: 20022176
references.citation: BMC Musculoskelet Disord. 2011 Jun 16;12:134
references.pmid: 21679434
references.citation: Pain. 2003 Sep;105(1-2):47-55
references.pmid: 14499419
references.citation: Pain. 2007 Apr;128(3):272-282
references.pmid: 17276007
references.citation: Pain. 2005 Apr;114(3):339-346
references.pmid: 15777859
references.citation: Pain. 2009 Jul;144(1-2):110-8
references.pmid: 19410369
references.citation: Neuroscience. 2008 Apr 9;152(4):1086-92
references.pmid: 18358622
references.citation: Neuroscience. 2010 Feb 17;165(4):1420-8
references.pmid: 19961904
references.citation: J Pain. 2003 May;4(4):203-11
references.pmid: 14622705
references.citation: J Neurosci. 2003 May 15;23(10):4017-22
references.pmid: 12764087
references.citation: Pain. 2002 Apr;96(3):253-260
references.pmid: 11972997
references.citation: Arthritis Rheum. 2010 Dec;62(12):3666-76
references.pmid: 20722027
references.citation: Exp Neurol. 2005 Apr;192(2):444-62
references.pmid: 15755561
references.citation: Physiol Res. 2009;58(3):419-425
references.pmid: 18637715
references.citation: Pain. 2010 Jun;149(3):573-581
references.pmid: 20418016
references.citation: Neuroreport. 1999 May 14;10(7):1461-5
references.pmid: 10380963
references.citation: Nature. 2005 Dec 15;438(7070):1017-21
references.pmid: 16355225
references.citation: J Clin Invest. 2009 Feb;119(2):287-94
references.pmid: 19127021
references.citation: Physiol Behav. 1997 Nov;62(5):951-4
references.pmid: 9333186
references.citation: Pain. 2005 Dec 5;118(3):327-335
references.pmid: 16289798
references.citation: Neurosci Lett. 2004 Nov 11;370(2-3):236-40
references.pmid: 15488329
references.citation: Ann Rheum Dis. 2011 Jan;70(1):60-7
references.pmid: 20829200
references.citation: Endocrinology. 1989 Jun;124(6):3125-7
references.pmid: 2785913
references.citation: Eur J Neurosci. 2000 Jun;12(6):1900-12
references.pmid: 10886331
references.citation: Pain. 2004 Nov;112(1-2):83-93
references.pmid: 15494188
references.citation: Mol Pain. 2011 May 20;7:39
references.pmid: 21599960
references.citation: J Neurosci. 2010 Apr 14;30(15):5437-50
references.pmid: 20392965
references.citation: J Neuroimmunol. 1997 Nov;79(2):163-75
references.pmid: 9394789
references.citation: Nat Rev Neurosci. 2009 Jan;10(1):23-36
references.pmid: 19096368
references.citation: Pain. 2005 Mar;114(1-2):149-59
references.pmid: 15733640
references.citation: J Pharmacol Exp Ther. 2003 Aug;306(2):624-30
references.pmid: 12734393
references.citation: Eur J Neurosci. 2004 Jul;20(2):467-73
references.pmid: 15233755
references.citation: Brain Res. 2011 Jan 25;1370:34-42
references.pmid: 21081117
references.citation: Lancet. 2005 Mar 12-18;365(9463):965-73
references.pmid: 15766999
references.citation: Arthritis Rheum. 2009 Sep 15;61(9):1226-34
references.pmid: 19714588
references.citation: Neurosci Lett. 2005 Nov 11;388(2):75-80
references.pmid: 16039054
references.citation: Neurochem Int. 2004 Jul-Aug;45(2-3):397-407
references.pmid: 15145554
references.citation: J Pathol. 2004 Nov;204(4):428-37
references.pmid: 15495269
references.citation: Pharmacol Ther. 2010 Apr;126(1):56-68
references.pmid: 20117131
references.citation: Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1702-14
references.pmid: 17299084
references.citation: Brain Res. 1991 Nov 22;565(1):1-7
references.pmid: 1723019